1. Ahlin A, Nyback H, Junthe T, Ohman G and Nordgren I (1991): THA in Alzheimer’s dementia — clinical, biochemical and pharmacokinetic findings. In: Alzheimer’s Disease — Basic Mechanisms, Diagnosis and Therapeutic Strategies, Iqbal K, McLachlan DRC, Winblad B and Wisniewski HM, eds. New York: Wiley Publishers, pp. 621–625.
2. Atack JR, Yu Q-S, Soncrant TT, Brossi A and Rapoport SI (1989): Comparative inhibitory effects of various physostigmine analogs against acetyl-and butyrylcholinesterases. J Pharm Exp Therap 249:194–202.
3. Bartus RT, Dean RL and Flicker C (1987): Cholinergic psychopharmacology — an integration of human and animal research on memory. In: Psychopharmacology: The Third Generation of Progress, Meltzer HY, ed. New York: Raven Press, pp. 219–232.
4. Becker RE and Giacobini E (1988a): Mechanisms of cholinesterase inhibition in Senile Dementia of the Alzheimer Type — Clinical, pharmacological and therapeutic aspects. Drug Dev Res 12:163–195.
5. Becker RE and Giacobini E (1988b): Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition — can acetylcholine levels in brain be improved in Alzheimer’s disease? Drug Dev Res 14:235–246.